Abbott Laboratories Wednesday said it closed the acquisition of Piramal Healthcare Ltd.’s generic drugs unit. In May, Abbott had agreed to buy Piramal’s healthcare solutions business for about $3.7 billion, Abbott Laboratories said in a statement.
Abbott completes acquisition of India’s Piramal
By Dow Jones Newswires
Posted Sep. 8, 2010 at 6:02 a.m.
